Skip to content
Catalyst

rebaudioside AWhat was measured

Measured, with no finding

32 endpoints

Show what was measuredHide what was measured
  • mean arterial pressure

    no effect, n = 100

    Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses

    PMID 18555574 · one of two readings recorded this

  • 24-h ambulatory blood pressure responses, device not stated

    no effect

    Not recorded as a finding: The ambulatory outcome node is systolic-specific and the sentence lumps unspecified 24-h blood pressures; no clean node match

    Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses.

    PMID 18555574 · one of two readings recorded this

  • 24-h ambulatory blood pressure responses

    no effect

    Not recorded as a finding: Sentence does not separate systolic from diastolic; the ambulatory node is systolic-only with device and valid-reading requirements the abstract never states

    Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses.

    PMID 18555574 · one of two readings recorded this

  • 24-h ambulatory blood pressure

    no effect, n = 100

    Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses

    PMID 18555574 · one of two readings recorded this

  • baseline resting seated DBP

    At baseline, mean resting, seated SBP/DBP was 110.0/70.3mmHg and 110.7/71.2mmHg for the rebaudioside A and placebo groups, respectively

    PMID 18555574 · one of two readings recorded this

  • baseline resting seated SBP

    At baseline, mean resting, seated SBP/DBP was 110.0/70.3mmHg and 110.7/71.2mmHg for the rebaudioside A and placebo groups, respectively

    PMID 18555574 · one of two readings recorded this

  • heart rate, resting seated, instrument not stated

    no effect

    Not recorded as a finding: No heart rate outcome node in the list

    Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses.

    PMID 18555574 · one of two readings recorded this

  • heart rate

    no effect, n = 100

    Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses

    PMID 18555574 · one of two readings recorded this

  • resting heart rate (HR)

    no effect

    Not recorded as a finding: No heart rate outcome node in the list

    Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses.

    PMID 18555574 · one of two readings recorded this

  • resting seated diastolic blood pressure

    no effect, n = 100

    Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses

    PMID 18555574 · one of two readings recorded this

  • resting seated systolic blood pressure

    no effect, n = 100

    Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses

    PMID 18555574 · one of two readings recorded this

  • blood pressure, body weight and fasting lipids, no instrument stated

    no effect

    Not recorded as a finding: Sentence is agentless and does not name rebaudioside A, and it groups several endpoints with no estimate

    Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment.

    PMID 18555575 · one of two readings recorded this

  • blood pressure, body weight and fasting lipids

    no effect

    Not recorded as a finding: Sentence is agentless (no compound named) and groups several endpoints with no estimate; also lipids not separable to a single node

    Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment.

    PMID 18555575 · one of two readings recorded this

  • change in blood pressure

    no effect

    Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment

    PMID 18555575 · one of two readings recorded this

  • change in body weight

    no effect

    Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment

    PMID 18555575 · one of two readings recorded this

  • change in C-peptide

    no effect

    C-peptide (0.13+/-0.09ng/mL and 0.42+/-0.14ng/mL)

    PMID 18555575 · one of two readings recorded this

  • change in fasting glucose

    no effect

    fasting glucose (7.5+/-3.7mg/dL and 11.2+/-4.5mg/dL)

    PMID 18555575 · one of two readings recorded this

  • change in fasting insulin

    no effect

    insulin (1.0+/-0.64microU/mL and 3.3+/-1.5microU/mL)

    PMID 18555575 · one of two readings recorded this

  • change in fasting lipids

    no effect

    Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment

    PMID 18555575 · one of two readings recorded this

  • change in glycosylated hemoglobin

    no effect, p = 0.355

    Mean+/-standard error changes in glycosylated hemoglobin levels did not differ significantly between the rebaudioside A (0.11+/-0.06%) and placebo (0.09+/-0.05%; p=0.355) groups

    PMID 18555575 · one of two readings recorded this

  • hypoglycemic episodes

    no effect

    Rebaudioside A was well-tolerated, and records of hypoglycemic episodes showed no excess vs. placebo

    PMID 18555575 · one of two readings recorded this

  • plasma steviol glucuronide Cmax and AUC0-t, tmax and t1/2, and urinary excretion after single oral rebaudioside A versus stevioside

    decreases, steviol glucuronide geometric mean Cmax approximately 22% lower after rebaudioside A (1472 ng/mL) than after stevioside (1886 ng/mL)

    Not recorded as a finding: the comparison was against another active treatment

    Administration of rebaudioside A resulted in a significantly (approximately 22%) lower steviol glucuronide geometric mean Cmax value (1472ng/mL) than administration of stevioside (1886ng/mL).

    PMID 18555578 · one of two readings recorded this

  • steviol glucuronide geometric mean AUC0-t

    decreases

    The geometric mean AUC0-t value for steviol glucuronide after administration of rebaudioside A (30,788ngh/mL) was approximately 10% lower than after administration of stevioside (34,090ngh/mL)

    PMID 18555578 · one of two readings recorded this

  • steviol glucuronide geometric mean Cmax

    decreases

    Administration of rebaudioside A resulted in a significantly (approximately 22%) lower steviol glucuronide geometric mean Cmax value (1472ng/mL) than administration of stevioside (1886ng/mL)

    PMID 18555578 · one of two readings recorded this

  • steviol glucuronide plasma Cmax, AUC0-t, tmax and half-life, and urinary and faecal excretion, after single oral doses of rebaudioside A versus stevioside

    decreases, approximately 22% lower steviol glucuronide geometric mean Cmax (1472 vs 1886 ng/mL) after rebaudioside A than after stevioside

    Not recorded as a finding: the comparison was against another active treatment

    Administration of rebaudioside A resulted in a significantly (approximately 22%) lower steviol glucuronide geometric mean Cmax value (1472ng/mL) than administration of stevioside (1886ng/mL).

    PMID 18555578 · one of two readings recorded this

  • AUC blood glucose 0-2 h during OGTT

    no effect, n = 30

    Rebaudioside A administration did not result in lower glycemia nor higher insulin or C-peptide concentrations compared to placebo, neither in the fasting state nor during the OGTT

    PMID 36057030 · one of two readings recorded this

  • AUC of blood glucose during a 75 g OGTT 19 h after dosing (AUCGlucose(0-2h)), with insulin and C-peptide concentrations and maximal glucose

    no effect

    Not recorded as a finding: the supporting sentence never names the compound

    The AUCs, glucose excursion and maximal glucose, insulin and C-peptide concentrations were also comparable for all these parameters in both conditions (and Table S2 of the Supplementary Information).

    PMID 36057030 · one of two readings recorded this

  • blood glucose, insulin and C-peptide AUCs, glucose excursion and maximal concentrations during a 75 g OGTT 19 h after a single 3 g dose, hexokinase method

    no effect

    Not recorded as a finding: the supporting sentence never names the compound

    The AUCs, glucose excursion and maximal glucose, insulin and C-peptide concentrations were also comparable for all these parameters in both conditions (and Table S2 of the Supplementary Information).

    PMID 36057030 · one of two readings recorded this

  • fasting-state glycemia, insulin and C-peptide

    no effect, n = 30

    Rebaudioside A administration did not result in lower glycemia nor higher insulin or C-peptide concentrations compared to placebo, neither in the fasting state nor during the OGTT

    PMID 36057030 · one of two readings recorded this

  • glucose excursion and maximal glucose, insulin and C-peptide concentrations

    no effect, n = 30

    The AUCs, glucose excursion and maximal glucose, insulin and C-peptide concentrations were also comparable for all these parameters in both conditions

    PMID 36057030 · one of two readings recorded this

  • serum C-peptide during OGTT

    no effect, n = 30

    Rebaudioside A administration did not result in lower glycemia nor higher insulin or C-peptide concentrations compared to placebo, neither in the fasting state nor during the OGTT

    PMID 36057030 · one of two readings recorded this

  • serum insulin during OGTT

    no effect, n = 30

    Rebaudioside A administration did not result in lower glycemia nor higher insulin or C-peptide concentrations compared to placebo, neither in the fasting state nor during the OGTT

    PMID 36057030 · one of two readings recorded this